C4 Therapeuticsinc Stock Cash Flow From Operations
| CCCC Stock | USD 5.68 0.29 4.86% |
C4 TherapeuticsInc fundamentals help investors to digest information that contributes to C4 TherapeuticsInc's financial success or failures. It also enables traders to predict the movement of CCCC Stock. The fundamental analysis module provides a way to measure C4 TherapeuticsInc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to C4 TherapeuticsInc stock.
CCCC | Cash Flow From Operations |
C4 TherapeuticsInc Company Cash Flow From Operations Analysis
C4 TherapeuticsInc's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current C4 TherapeuticsInc Cash Flow From Operations | (106.84 M) |
Most of C4 TherapeuticsInc's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, C4 TherapeuticsInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CCCC Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for C4 TherapeuticsInc is extremely important. It helps to project a fair market value of CCCC Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since C4 TherapeuticsInc's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of C4 TherapeuticsInc's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of C4 TherapeuticsInc's interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, C4 TherapeuticsInc has (106.84 Million) in Cash Flow From Operations. This is 120.26% lower than that of the Biotechnology sector and 270.87% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 111.0% higher than that of the company.
CCCC Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses C4 TherapeuticsInc's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of C4 TherapeuticsInc could also be used in its relative valuation, which is a method of valuing C4 TherapeuticsInc by comparing valuation metrics of similar companies.C4 TherapeuticsInc is currently under evaluation in cash flow from operations category among related companies.
C4 TherapeuticsInc Current Valuation Drivers
We derive many important indicators used in calculating different scores of C4 TherapeuticsInc from analyzing C4 TherapeuticsInc's financial statements. These drivers represent accounts that assess C4 TherapeuticsInc's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of C4 TherapeuticsInc's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.1B | 1.4B | 1.5B | 288.3M | 280.5M | 266.4M | |
| Enterprise Value | 1.0B | 1.3B | 1.4B | 345.7M | 224.9M | 213.6M |
C4 TherapeuticsInc ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, C4 TherapeuticsInc's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to C4 TherapeuticsInc's managers, analysts, and investors.Environmental | Governance | Social |
CCCC Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (11.48) % | ||||
| Current Valuation | 283.09 M | ||||
| Shares Outstanding | 68.81 M | ||||
| Shares Owned By Insiders | 11.58 % | ||||
| Shares Owned By Institutions | 75.00 % | ||||
| Number Of Shares Shorted | 10.14 M | ||||
| Price To Book | 2.07 X | ||||
| Price To Sales | 24.49 X | ||||
| Revenue | 20.76 M | ||||
| Gross Profit | (86.75 M) | ||||
| EBITDA | (131.29 M) | ||||
| Net Income | (132.49 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 70.98 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 4.07 X | ||||
| Cash Flow From Operations | (106.84 M) | ||||
| Short Ratio | 4.55 X | ||||
| Earnings Per Share | (2.67) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 18.75 | ||||
| Number Of Employees | 145 | ||||
| Beta | 3.19 | ||||
| Market Capitalization | 390.82 M | ||||
| Total Asset | 376.45 M | ||||
| Retained Earnings | (528.38 M) | ||||
| Working Capital | 228.42 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
| Net Asset | 376.45 M |
About C4 TherapeuticsInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze C4 TherapeuticsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 TherapeuticsInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 TherapeuticsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 TherapeuticsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 TherapeuticsInc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeuticsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeuticsinc Stock:Check out C4 TherapeuticsInc Piotroski F Score and C4 TherapeuticsInc Altman Z Score analysis. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.Note that the C4 TherapeuticsInc information on this page should be used as a complementary analysis to other C4 TherapeuticsInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for CCCC Stock analysis
When running C4 TherapeuticsInc's price analysis, check to measure C4 TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 TherapeuticsInc is operating at the current time. Most of C4 TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of C4 TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 TherapeuticsInc's price. Additionally, you may evaluate how the addition of C4 TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is C4 TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 TherapeuticsInc. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.67) | Revenue Per Share 0.418 | Quarterly Revenue Growth 0.143 | Return On Assets (0.22) | Return On Equity (0.49) |
The market value of C4 TherapeuticsInc is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is C4 TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 TherapeuticsInc's market value can be influenced by many factors that don't directly affect C4 TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.